FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200579769> ?p ?o ?g. }

• W4200579769 endingPage "916" @default.
• W4200579769 startingPage "907" @default.
• W4200579769 abstract "Molecular tumour boards (MTB) optimally match oncological therapies to patients with genetic aberrations. Prostate cancer (PCa) is underrepresented in these MTB discussions. This study describes the impact of routine genetic profiling and MTB referral on the outcome of PCa patients in a tertiary referral centre.All PCa patients that received next-generation sequencing results and/or were discussed at an MTB between Jan 1, 2017 and Jan 1, 2020 were included. Genetically matched therapies (GMT) in clinical trials or compassionate use were linked to actionable alterations. Response to these agents was retrospectively evaluated.Out of the 277 genetically profiled PCa patients, 215 (78%) were discussed in at least one MTB meeting. A GMT was recommended to 102 patients (47%), of which 63 patients (62%) initiated the GMT. The most recommended therapies were PARP inhibitors (n = 74), programmed death-(ligand) 1 inhibitors (n = 21) and tyrosine kinase inhibitors (n = 19). Once started, 41.3% had a PFS of ≥6 months, 43.5% a PSA decline ≥50% and 38.5% an objective radiographic response.Recommendation for a GMT is achieved in almost half of the patients with advanced prostate cancer, with GMT initiation leading to durable responses in over 40% of patients. These data justify routine referral of selected PCa patients to MTB's." @default.
• W4200579769 created "2021-12-31" @default.
• W4200579769 creator A5003163093 @default.
• W4200579769 creator A5024569299 @default.
• W4200579769 creator A5034875458 @default.
• W4200579769 creator A5036825889 @default.
• W4200579769 creator A5039709555 @default.
• W4200579769 creator A5045117537 @default.
• W4200579769 creator A5051650713 @default.
• W4200579769 creator A5051977856 @default.
• W4200579769 creator A5058463503 @default.
• W4200579769 creator A5060302039 @default.
• W4200579769 creator A5085138741 @default.
• W4200579769 date "2021-12-15" @default.
• W4200579769 modified "2023-10-14" @default.
• W4200579769 title "Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer" @default.
• W4200579769 cites W1578291413 @default.
• W4200579769 cites W2019607817 @default.
• W4200579769 cites W2042210471 @default.
• W4200579769 cites W2051978340 @default.
• W4200579769 cites W2102335858 @default.
• W4200579769 cites W2104287359 @default.
• W4200579769 cites W2127250774 @default.
• W4200579769 cites W2136636834 @default.
• W4200579769 cites W2148987788 @default.
• W4200579769 cites W2235380567 @default.
• W4200579769 cites W2278392405 @default.
• W4200579769 cites W2520761147 @default.
• W4200579769 cites W2530746957 @default.
• W4200579769 cites W2557342435 @default.
• W4200579769 cites W2566723262 @default.
• W4200579769 cites W2586872730 @default.
• W4200579769 cites W2591662301 @default.
• W4200579769 cites W2601520864 @default.
• W4200579769 cites W2620581814 @default.
• W4200579769 cites W2664930764 @default.
• W4200579769 cites W2681535791 @default.
• W4200579769 cites W2730739416 @default.
• W4200579769 cites W2757648331 @default.
• W4200579769 cites W2795373371 @default.
• W4200579769 cites W2832093183 @default.
• W4200579769 cites W2886569874 @default.
• W4200579769 cites W2887809138 @default.
• W4200579769 cites W2888034354 @default.
• W4200579769 cites W2908503672 @default.
• W4200579769 cites W2922348865 @default.
• W4200579769 cites W2922463680 @default.
• W4200579769 cites W2924972479 @default.
• W4200579769 cites W2945522282 @default.
• W4200579769 cites W2946384906 @default.
• W4200579769 cites W2956010369 @default.
• W4200579769 cites W2972985040 @default.
• W4200579769 cites W2976525441 @default.
• W4200579769 cites W2980198494 @default.
• W4200579769 cites W2990771207 @default.
• W4200579769 cites W2997243361 @default.
• W4200579769 cites W3011518560 @default.
• W4200579769 cites W3012780724 @default.
• W4200579769 cites W3014041788 @default.
• W4200579769 cites W3014230640 @default.
• W4200579769 cites W3016483659 @default.
• W4200579769 cites W3020771563 @default.
• W4200579769 cites W3030097558 @default.
• W4200579769 cites W3031516802 @default.
• W4200579769 cites W3048583805 @default.
• W4200579769 cites W3049351332 @default.
• W4200579769 cites W3080458669 @default.
• W4200579769 cites W3083951977 @default.
• W4200579769 cites W3087416729 @default.
• W4200579769 cites W3088602042 @default.
• W4200579769 cites W3088774441 @default.
• W4200579769 cites W3093610955 @default.
• W4200579769 cites W3097377793 @default.
• W4200579769 cites W3119005666 @default.
• W4200579769 cites W3134411589 @default.
• W4200579769 cites W3136168714 @default.
• W4200579769 cites W3182939006 @default.
• W4200579769 cites W3190141894 @default.
• W4200579769 cites W3191534679 @default.
• W4200579769 doi "https://doi.org/10.1038/s41416-021-01663-9" @default.
• W4200579769 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34912074" @default.
• W4200579769 hasPublicationYear "2021" @default.
• W4200579769 type Work @default.
• W4200579769 citedByCount "3" @default.
• W4200579769 countsByYear W42005797692022 @default.
• W4200579769 countsByYear W42005797692023 @default.
• W4200579769 crossrefType "journal-article" @default.
• W4200579769 hasAuthorship W4200579769A5003163093 @default.
• W4200579769 hasAuthorship W4200579769A5024569299 @default.
• W4200579769 hasAuthorship W4200579769A5034875458 @default.
• W4200579769 hasAuthorship W4200579769A5036825889 @default.
• W4200579769 hasAuthorship W4200579769A5039709555 @default.
• W4200579769 hasAuthorship W4200579769A5045117537 @default.
• W4200579769 hasAuthorship W4200579769A5051650713 @default.
• W4200579769 hasAuthorship W4200579769A5051977856 @default.
• W4200579769 hasAuthorship W4200579769A5058463503 @default.
• W4200579769 hasAuthorship W4200579769A5060302039 @default.
• W4200579769 hasAuthorship W4200579769A5085138741 @default.

• next